| Current Price | $83.64 | Mkt Cap | $184.9B |
|---|---|---|---|
| Open | $83.71 | P/E Ratio | 15.94 |
| Prev. Close | $83.64 | Div. (Yield) | $2.01 (2.4%) |
| Daily Range | $82.79 - $84.20 | Volume | 156,310 |
| 52-Wk Range | $69.31 - $99.82 | Avg. Daily Vol. | 3,250,099 |
Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products.
| Current Price | $83.64 | Mkt Cap | $184.9B |
|---|---|---|---|
| Open | $83.71 | P/E Ratio | 15.94 |
| Prev. Close | $83.64 | Div. (Yield) | $2.01 (2.4%) |
| Daily Range | $82.79 - $84.20 | Volume | 156,310 |
| 52-Wk Range | $69.31 - $99.82 | Avg. Daily Vol. | 3,250,099 |
The best Bull and Bear pitches based on recency and number of recommendations.
Dividend, M & A activity, and pipeline.
After a good run in the past couple months, NVS looks poised to underperform the S&P. Not that I think its going to take a fall, more so that the S&P will be playing catchup for the next couple of months while NVS hangs around somewhat.
Read the most recent pitches from players about NVS.
Recs
jbswen
(< 20)
Submitted: 3/27/2020 2:10:51 PM :
Start Price:
$79.17
NYSE:NVS Score:
+8.73
With this epidemic and once the find a cure they are for sure to take off
Recs
TMFAdriaCimino
(75.19)
Submitted: 2/20/2020 4:29:31 AM :
Start Price:
$95.16
NYSE:NVS Score:
+14.43
The flow of newly approved drugs will lift revenue over the long term, making me bullish on the stock.
Recs
TMFmarkprvulovic
(42.13)
Submitted: 10/17/2019 4:21:14 AM :
Start Price:
$82.06
NYSE:NVS Score:
+16.29
Growing revenues among most major drugs, with its top therapy seeing an impressive 23% increase in quarterly revenue. Updated clinical results for breast cancer drug are also highly impressive.
Find the members with the highest scoring picks in NVS.
claygrant1974 (39.39) Score: +114.09
The Score Leader is the player with the highest score across all their picks in NVS.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| EvilUnicorn | 60.19 | 10/29/2007 |
|
5Y | $36.24 | +130.80% | +68.85% | +61.95 | 0 Comment | |
| celtic7 | 23.34 | 10/29/2007 |
|
1Y | $36.32 | +130.26% | +68.90% | +61.36 | 0 Comment | |
| gkorneev | 60.01 | 10/29/2007 |
|
5Y | $36.32 | +130.26% | +68.90% | +61.36 | 0 Comment | |
| marionvb | 30.45 |
|
|
5Y | $36.32 | +130.26% | +68.90% | +61.36 | 1 Comment | |
| pdt24 | 39.06 | 4/17/2008 |
|
5Y | $33.47 | +149.89% | +88.76% | +61.14 | 0 Comment | |
| hickeyme | 96.38 | 4/17/2008 |
|
1Y | $33.56 | +149.24% | +88.96% | +60.27 | 0 Comment | |
| mfinzel | 99.73 | 10/26/2007 |
|
5Y | $36.46 | +129.42% | +69.63% | +59.79 | 0 Comment | |
|
1slimWin | < 20 | 4/18/2008 |
|
NS | $34.07 | +145.46% | +85.80% | +59.66 | 0 Comment |
| thidmark | < 20 | 4/18/2008 |
|
5Y | $34.07 | +145.46% | +85.80% | +59.66 | 0 Comment | |
| Pressonj | < 20 | 10/30/2007 |
|
3W | $36.59 | +128.59% | +69.43% | +59.16 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
